Nothing Special   »   [go: up one dir, main page]

JOP20220193A1 - صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها - Google Patents

صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها

Info

Publication number
JOP20220193A1
JOP20220193A1 JOP/2022/0193A JOP20220193A JOP20220193A1 JO P20220193 A1 JOP20220193 A1 JO P20220193A1 JO P20220193 A JOP20220193 A JO P20220193A JO P20220193 A1 JOP20220193 A1 JO P20220193A1
Authority
JO
Jordan
Prior art keywords
methods
formulations
same
human anti
tslp antibodies
Prior art date
Application number
JOP/2022/0193A
Other languages
English (en)
Inventor
Lauren Roschen
Jennifer Litowski
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20220193A1 publication Critical patent/JOP20220193A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير تركيبات تشتمل على أكبر من حوالي 100 مجم/ ملليلتر من جسم مضاد لـ TSLP، منشط سطح، برولين، ومحلول منظم مشتمل على أكبر من حوالي 100 مجم/ ملليلتر من جسم مضاد لـ TSLP، منشط سطح، برولين، ومحلول منظم. يتم إضافيًا توفير طرق لعلاج مرض التهابي في كائن.
JOP/2022/0193A 2020-02-18 2021-02-18 صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها JOP20220193A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978201P 2020-02-18 2020-02-18
PCT/US2021/018561 WO2021168100A1 (en) 2020-02-18 2021-02-18 Formulations of human anti-tslp antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
JOP20220193A1 true JOP20220193A1 (ar) 2023-01-30

Family

ID=74860588

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0193A JOP20220193A1 (ar) 2020-02-18 2021-02-18 صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها

Country Status (19)

Country Link
US (1) US20230081261A1 (ar)
EP (1) EP4106811A1 (ar)
JP (1) JP2023513833A (ar)
KR (1) KR20220143699A (ar)
CN (1) CN115151276A (ar)
AR (1) AR121368A1 (ar)
AU (1) AU2021221998A1 (ar)
BR (1) BR112022016456A2 (ar)
CA (1) CA3167975A1 (ar)
CL (1) CL2022002251A1 (ar)
CO (1) CO2022013251A2 (ar)
CR (1) CR20220465A (ar)
IL (1) IL295511A (ar)
JO (1) JOP20220193A1 (ar)
MX (1) MX2022010120A (ar)
PE (1) PE20230115A1 (ar)
TW (1) TW202144004A (ar)
UY (1) UY39089A (ar)
WO (1) WO2021168100A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4145105A1 (de) * 2021-09-06 2023-03-08 Anacyte Laboratories GmbH Lösung für die asservierung von zellen
AU2022348783A1 (en) * 2021-09-18 2024-10-03 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Composition comprising pd-l1 antigen-binding fragment and use thereof
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024092064A1 (en) * 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof
WO2024146630A1 (zh) * 2023-01-06 2024-07-11 江苏恒瑞医药股份有限公司 一种tslp抗体治疗哮喘的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
MY162511A (en) 2009-11-04 2017-06-15 Merck Sharp & Dohme Engineered anti-tslp antibody
TW201201840A (en) 2010-07-15 2012-01-16 Hoffmann La Roche Antibodies specifically binding to human TSLPR and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
US20160264658A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited TSLP Binding Proteins
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
WO2018200533A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
AU2018364933B2 (en) 2017-11-10 2024-01-25 Amgen Inc. Plungers for drug delivery devices
JP2021516672A (ja) 2018-03-13 2021-07-08 アムジエン・インコーポレーテツド 質量分光測定分析のためのトリプシン耐性ポリペプチドを調製するための方法
JP2022504769A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
TWI846741B (zh) 2018-10-15 2024-07-01 美商安進公司 用於藥物遞送裝置之平台組裝方法

Also Published As

Publication number Publication date
AR121368A1 (es) 2022-06-01
BR112022016456A2 (pt) 2022-10-04
KR20220143699A (ko) 2022-10-25
CL2022002251A1 (es) 2023-04-14
WO2021168100A1 (en) 2021-08-26
CO2022013251A2 (es) 2022-12-20
US20230081261A1 (en) 2023-03-16
IL295511A (en) 2022-10-01
UY39089A (es) 2021-08-31
PE20230115A1 (es) 2023-01-27
CR20220465A (es) 2023-03-30
EP4106811A1 (en) 2022-12-28
CN115151276A (zh) 2022-10-04
CA3167975A1 (en) 2021-08-26
TW202144004A (zh) 2021-12-01
AU2021221998A1 (en) 2022-09-15
MX2022010120A (es) 2022-09-05
JP2023513833A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
JOP20220193A1 (ar) صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها
JO3000B1 (ar) مركبات أجسام مضادة .
TW200602078A (en) Uses of anti-CTLA-4 antibodies
MX2019014023A (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
IN2012DN00313A (ar)
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
MY163480A (en) Sclerostin binding agents
SG163598A1 (en) Lawsonia vaccine and methods of use thereof
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
CR20220047A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
Kim et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
MX2023000499A (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2024011189A3 (en) Methods of treating disease using anti-il1rap antibodies and antibody drug conjugates
MX2022014455A (es) Formulacion de anticuerpo anti-clever-1 estable.
WO2021257695A8 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
MX2022009549A (es) Tratamiento que implica vacunacion con antigeno y agentes de union que se unen a pd-l1 y cd137.